(Q33418735)

English

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Stephen A. Strickland

object named as

Stephen A Strickland

11

0 references

17

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gautam Borthakur

13

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard D Leavitt

16

object named as

Richard D Leavitt

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

object named as

Wendy Stock

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Larry D Cripe

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

object named as

Paul J Shami

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Robert K Stuart

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael B Maris

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maureen A Cooper

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard M Stone

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shaker R Dakhil

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francesco Turturro

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James Mason

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Luciano J Costa

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Glenn C Michelson

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Judith A Fox

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

17 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

168

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

796-805

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Acute myeloid leukaemia in the elderly: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Therapeutic advances in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Age and acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Planned versus attained design in phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4354261

21 June 2018

Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13214

21 January 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13214

21 January 2018

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/25403830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The outcomes and costs of acute myeloid leukemia among the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/25403830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJH.13214

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33418735&oldid=1856486008"